Bayer, Celera to develop cancer drugs
BERLIN A U.S. company has entered an agreement with Bayer’s pharmaceutical division to develop cancer drugs.
Bayer Schering Pharma announced that it entered into an exclusive license agreement with Celera Corp., gaining access to five of Celera’s investigative cancer drugs.
Under the terms of the agreement, Bayer will pay Celera a one-time fee for exclusive access to the drugs, as well as potential milestone payments. Celera also is entitled to royalties on any products that reach the market.
“This agreement allows us to expand our existing research portfolio in the area of cancer-related targets,” Bayer Schering Pharma target discovery head Khusru Asadullah stated. “We look forward to exploring the full potential of these promising target candidates with regard to therapeutic interference for anti-tumor therapy as well as in in-vivo diagnostic imaging.”
NACDS Marketplace Conference kicks off with Meet the Market format
BOSTON It was a cool and crisp day as attendees filed into the Boston Convention & Exhibition Center Sunday to take part in the National Association of Chain Drug Stores Marketplace Conference annualized Meet the Market format, which this year represented more than 8,000 face-to-face pre-arranged appointments, including 270 retailers representing some 80 companies.
The Meet the Market format, where smaller and new suppliers are able to secure 10-minute meetings with their category buyers, takes on greater value in a recession economy, where many retailers are cutting more SKUs from their planograms than they’re slicing in, noted Larry Lotridge, NACDS VP conference services. “We know when the economy’s tight you still want to get in front of the retailers,” he said, “because our industry is still selling.”
Lotridge noted one supplier last year negotiated a 100-store test run in Walmart after an initial meeting at Meet the Market. This year, Lotridge said, that supplier is likely to secure full distribution with the mass marketer. “You want to be the company with the product on the shelf,” he said.
And such formats as Meet the Market are opportune to help new or small companies accomplish just that.
NACDS, NCPA endorse Rep. Mike Ross’ MTM legislation
ALEXANDRIA, Va. Two pharmacist organizations announced their support for H.R. 3108, the Medication Therapy Management Benefits Act of 2009, sponsored by Rep. Mike Ross, D-Ark.
The bill was introduced on June 26, and immediately was referred to the Committee on Energy and Commerce and Committee on Ways and Means, two House committees with jurisdiction over comprehensive healthcare reform legislation.
Pharmacist-provided medication therapy management involves a licensed pharmacist’s work with a patient to review, monitor and identify problems with a patient’s medication plan.
“We appreciate the hard work and dedication of Rep. Ross as he continues to advocate for pro-patient and pro-pharmacy healthcare reform legislation in Congress,” stated National Association of Chain Drug Stores president and CEO Steve Anderson. “Rep. Ross’ bill signifies the importance of pharmacist-provided medication therapy management for improving medication adherence, enhancing patient health and reducing long-term healthcare costs.”
National Community Pharmacists Association EVP and CEO Bruce Roberts also supported the bill, stating that MTM improves patients’ adherence and their outcomes through the utilization of pharmacists’ expertise. “H.R. 3108 will expand the pool of Medicare Part D patients that can access this valuable service and recognize pharmacists for the savings they provide to the healthcare system,” Roberts said. “We thank Congressman Mike Ross for introducing this bill, and urge other members of the House to support it. We call on the Senate to introduce similar legislation. Ultimately, for healthcare reform to be fully successful, it must include proposals such as this to improve quality while lowering overall costs.”